{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-22-000154","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.812127+00:00","generated_at":"2026-06-22T05:16:32.021642+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sesen Bio reports Q3 net income $20.5M, announces merger with Carisma Therapeutics","bullets":["Merger with Carisma: Sesen stockholders own ~41.7%, Carisma ~58.3% of combined company with ~$180M cash.","Sesen stockholders to receive CVR for potential Roche payments related to EBI-031 asset sale.","Combined company led by Carisma management; focus on CAR-M therapies for cancer.","Q3 revenue $40M from Roche asset sale; net income $20.5M ($0.10 per diluted share).","Cash $184.9M as of Sep 30, 2022; restructuring charges $10.9M from pausing Vicineum development."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-22-000154","json":"https://secwatch.observer/filing/0001485003-22-000154.json","markdown":"https://secwatch.observer/filing/0001485003-22-000154.md","text":"https://secwatch.observer/filing/0001485003-22-000154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/0001485003-22-000154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/sesnform3q2022earningsrele.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:16:32.021642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6cc5f1b49c4a16119911237552c69d0eb29a142","claim":"Carisma Therapeutics Inc. reported the third quarter ended September 30, 2022 results: revenue $40.0 million.","evidence_excerpt":"30, 2022, compared to cash and cash equivalents of $162.6 million as of December 31, 2021. • Total Revenue: Total revenue for the three months ended September 30, 2022 was $40.0 million, which was due to the execution of the Roche Asset Purchase Agreement. • R&D Expenses: Research and development expenses were $2.9 million for the three months ended September","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/0001485003-22-000154-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$40.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}